Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2013

01-10-2013 | Original Article

Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy

Authors: Takahide Taguchi, Goshi Nishimura, Masahiro Takahashi, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Yasuhiro Arai, Yukiko Yamashita, Osamu Shiono, Mariko Hirama, Yasunori Sakuma, Jun-ichi Ishitoya, Masaharu Hata, Ichiro Ogino, Nobuhiko Oridate

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2013

Login to get access

Abstract

Objective

To review our experience with concurrent chemoradiotherapy (CCRT) for patients with advanced resectable squamous cell carcinoma (SCC) of the larynx and to evaluate the factors affecting survival and larynx preservation.

Study design

Retrospective study.

Subjects and methods

The records of 102 patients with stage III or IV resectable SCC of the larynx treated with CCRT between February 1994 and March 2009 were reviewed. Of 102 patients, 59 were treated with high-dose regimens, including cisplatin, 5-fluorouracil (5-FU), methotrexate, and leucovorin or docetaxel, cisplatin, and 5-FU, and 43 were treated with low-dose regimens, including carboplatin and uracil-tegafur or S-1. Radiotherapy was delivered 5 days a week using a single daily fraction of 1.8–2.0 Gray (Gy), to a total dose of 66.0–70.2 Gy. Overall survival (OS), disease-specific survival (DSS), and DSS with larynx preservation were estimated using Kaplan–Meier methods. The log-rank test and Cox proportional hazards regression were used to identify significant prognostic factors for DSS and DSS with larynx preservation.

Results

The 5-year OS and DSS for all patients treated with CCRT were 63.9 and 70.7 %, respectively. The 5-year DSS with larynx preservation was 54.1 %. On multivariate analysis, N stage, synchronous multiple primary cancers, and the contents of chemotherapy were significant predictors of OS for patients undergoing CCRT; T stage, N stage, and the contents of chemotherapy were significant prognostic factors for larynx preservation.

Conclusion

The treatment method including the indication for CCRT may be determined by the contents of the chemotherapy and the T and N stages of laryngeal SCC. It is important to diagnose multiple synchronous primary cancers before CCRT.
Literature
1.
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer (1991) The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324(24):1685–1690
2.
Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091–2098PubMedCrossRef
3.
Katori H, Tsukuda M, Mochimatu I et al (2004) Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 90(2):348–352PubMedCrossRef
4.
Taguchi T, Tsukuda M, Mikami Y et al (2006) Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx. Acta Otolaryngol 126(4):408–413PubMedCrossRef
5.
Taguchi T, Ikeda Y, Mikami Y et al (2003) Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma. Anticancer Res 23(1B):713–717PubMed
6.
Tsukuda M, Ishitoya J, Mikami Y et al (2009) Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 64(5):945–952PubMedCrossRef
7.
Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355(9208):949–955PubMed
8.
Seiwert TY, Cohen EE (2005) State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92(8):1341–1348PubMedCrossRef
9.
Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852PubMedCrossRef
10.
Jeremic B, Milicic B (2009) Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol 32(2):163–168PubMedCrossRef
11.
Lodder WL, Pameijer FA, Rasch CR, van den Brekel MW, Balm AJ (2012) Prognostic significance of radiologically determined neck node volume in head and neck cancer: a systematic review. Oral Oncol 48(4):298–302PubMedCrossRef
12.
Jakobsen J, Hansen O, Jorgensen KE, Bastholt L (1998) Lymph node metastases from laryngeal and pharyngeal carcinomas–calculation of burden of metastasis and its impact on prognosis. Acta Oncol 37(5):489–493PubMedCrossRef
13.
Suntharalingam M, Haas ML, Van Echo DA et al (2001) Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 91(3):548–554PubMedCrossRef
14.
Douple EB, Richmond RC, O’Hara JA, Coughlin CT (1985) Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 12(suppl A):111–124PubMedCrossRef
15.
Colevas AD, Posner MR (1998) Docetaxel in head and neck cancer: a review. Am J Clin Oncol 21(5):482–486PubMedCrossRef
16.
Fu KK, Phillips TL (1991) Biologic rationale of combined radiotherapy and chemotherapy. In: Hematol Oncol Clin North Am :737–751
17.
Smalley SR, Kimler BF, Evans RG (1991) 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 20(2):207–211PubMedCrossRef
18.
Esposito ED, Bevilacqua L, Guadagno MT (2000) Multiple primary malignant neoplasm in patients with laryngeal carcinoma. J Surg Oncol 74(1):83–86PubMedCrossRef
19.
Nikolaou AC, Markou CD, Petridis DG, Daniilidis IC (2000) Second primary neoplasms in patients with laryngeal carcinoma. Laryngoscope 110(1):58–64PubMedCrossRef
20.
Yabuki K, Kubota A, Horiuchi C, Taguchi T, Nishimura G, Inamori M (2013) Limitations of PET and PET/CT in detecting upper gastrointestinal synchronous cancer in patients with head and neck carcinoma. Eur Arch Otorhinolaryngol 270(2):727–733PubMedCrossRef
21.
Ikeda Y, Tsukuda M, Ishitoya J et al (2005) Four cases of simultaneous triple primary cancers of the hypopharynx, esophagus, and stomach. Otolaryngol Head Neck Surg 132(5):788–793PubMedCrossRef
22.
Brockstein B, Haraf DJ, Rademaker AW et al (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15(8):1179–1186PubMedCrossRef
23.
Knegjens JL, Hauptmann M, Pameijer FA et al (2011) Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck 33(3):375–382PubMed
24.
Stenson KM, Maccracken E, Kunnavakkam R et al (2012) Chemoradiation for patients with large-volume laryngeal cancers. Head Neck 34(8):1162–1167PubMedCrossRef
25.
Knab BR, Salama JK, Solanki A et al (2008) Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol 19(9):1650–1654PubMedCrossRef
Metadata
Title
Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy
Authors
Takahide Taguchi
Goshi Nishimura
Masahiro Takahashi
Masanori Komatsu
Daisuke Sano
Naoko Sakuma
Yasuhiro Arai
Yukiko Yamashita
Osamu Shiono
Mariko Hirama
Yasunori Sakuma
Jun-ichi Ishitoya
Masaharu Hata
Ichiro Ogino
Nobuhiko Oridate
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-013-2261-3

Other articles of this Issue 4/2013

Cancer Chemotherapy and Pharmacology 4/2013 Go to the issue

Original Article

A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer

Short Communication

Antitumor efficacy, toxicity and pharmacokinetics of 9-nitrocamptothecin: role of lactone ratio

Original Article

Disruption of ZO-1/claudin-4 interaction in relation to inflammatory responses in methotrexate-induced intestinal mucositis

Original Article

Clinical evaluation of targeted arterial perfusion of verapamil and chemotherapeutic drugs in interventional therapy of advanced lung cancer

Original Article

Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients

Original Article

A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits